Injective CEO Holds US Talks on Tokenized Finance
Injective CEO Eric Chen met with White House, SEC and CFTC officials in October to discuss regulated onchain finance and real-world asset (RWA) tokenization. The company disclosed no specific outcomes or new approvals.
The talks build on Injective’s SEC transfer agent registration in August 2026, which allows it to maintain ownership records for tokenized securities. Injective says its network hosts more than $1 billion in tokenized RWA value and has recorded over $5.3 billion in cumulative RWA perpetual trading volume. The company has also advocated for a development window for DeFi projects, while the SEC’s Innovation Exemption may create new pathways for financial technology.
For traders, the meetings signal continued engagement between crypto firms and US regulators, but do not guarantee more permissive rules. Any longer-term boost to Injective or tokenized assets will depend on regulatory decisions and institutional adoption; the reported network figures are company-provided.
Neutral
The meetings are a constructive sign of regulatory engagement, but the article reports no new approvals, policy commitments or immediate changes to Injective’s market access. As a result, the direct trading impact is likely limited, and the news alone does not establish a clear bullish or bearish catalyst for INJ.
In the short term, traders may watch for follow-up announcements and shifts in sentiment around US crypto regulation, tokenized assets and DeFi. Similar policy discussions have often produced brief sentiment moves, while prices have depended more on concrete rule changes, exchange listings, liquidity and broader market conditions. The company-reported RWA figures may support interest in Injective, but should not be treated as independently verified adoption or guaranteed demand for INJ.
Longer term, clearer rules and institutional participation could support tokenization and onchain finance, potentially benefiting Injective if it attracts sustained activity. However, regulatory momentum can stall or reverse, and the SEC’s Innovation Exemption will matter only if its eligibility and terms prove workable. Traders should distinguish the positive signal of access to policymakers from actual regulatory outcomes.